A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis -: Implications for phase II clinical trials

被引:109
作者
Filippi, M
Rovaris, M
Capra, R
Gasperini, C
Yousry, TA
Sormani, MP
Prandini, F
Horsfield, MA
Martinelli, V
Bastianello, S
Kühne, I
Pozzilli, C
Comi, G
机构
[1] Univ Milan, Osped San Raffaele, Inst Sci, Dept Neurosci,Neuroimaging Res Unit, I-20132 Milan, Italy
[2] Univ Milan, Osped San Raffaele, Inst Sci, Dept Neurosci,Unit Clin Trials, I-20132 Milan, Italy
[3] Univ Brescia, Spedali Civili, Dept Neurol, Brescia, Italy
[4] Univ Brescia, Spedali Civili, Dept Neuroradiol, Brescia, Italy
[5] Univ La Sapienza, Dept Neurol, Rome, Italy
[6] Univ La Sapienza, Dept Neuroradiol, Rome, Italy
[7] Natl Inst Canc Res, Dept Clin Epidemiol & Trials, Genoa, Italy
[8] Univ Munich, Klinikum Grosshadern, Dept Neuroradiol, D-8000 Munich, Germany
[9] Univ Leicester, Div Med Phys, Leicester, Leics, England
关键词
multiple sclerosis; MRI; gadolinium-DTPA; triple dose; disease activity;
D O I
10.1093/brain/121.10.2011
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In this study we assessed the safety, efficacy and cost-effectiveness of the use of triple dose gadolinium-DTPA (Gd) in serial monthly brain MRI of patients with multiple sclerosis, such as could be selected for clinical trials. The number of enhancing lesions, the number of new enhancing lesions and the number of active scans were used to evaluate the sensitivity of the contrast-enhanced MRI to disease activity. The dose of Gd, and the effect of introducing a delay between the contrast injection and the scan were both appraised. Every 4 weeks for 3 months, and in two separate sessions, scans were obtained from 40 patients with relapsing-remitting or secondary progressive multiple sclerosis, 5 min (early) and 20 min (delayed) after a standard dose (0.1 mmol/kg) or triple dose (0.3 mmol/kg) Gd injection, There were 435 enhancing lesions (242 of which were new) on the early standard dose scans, 479 (263 new) on the delayed standard dose, 772 (365 new) on the early triple dose and 827 (404 ne cr) on the delayed triple dose. There were 109 scans revealing active disease on the early standard dose scans, 112 on the delayed standard dose, 119 on the early triple dose and 120 on the delayed triple dose, Statistical simulations indicated that the sample sizes needed for both cross-over and parallel-group trials with similar powers are lower if serial monthly triple dose MRI is used. No side-effects were reported and no significant changes in blood test parameters were found throughout the study. This study shows that the serial use of triple dose Gd is safe, and that it increases the sensitivity of serial monthly enhanced MRI in detecting multiple sclerosis activity significantly. Its use should enable preliminary trials of experimental therapies for multiple sclerosis to be conducted in small patient populations, over a short period of time.
引用
收藏
页码:2011 / 2020
页数:10
相关论文
共 49 条
  • [1] Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis
    Barkhof, F
    Filippi, M
    van Waesberghe, JH
    Molyneux, P
    Rovaris, M
    Nijeholt, GLA
    Tubridy, N
    Miller, DH
    Yousry, TA
    Radue, EW
    Adèr, HJ
    [J]. NEUROLOGY, 1997, 49 (06) : 1682 - 1688
  • [2] QUANTITATIVE MRI CHANGES IN GADOLINIUM-DTPA ENHANCEMENT AFTER HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE IN MULTIPLE-SCLEROSIS
    BARKHOF, F
    HOMMES, OR
    SCHELTENS, P
    VALK, J
    [J]. NEUROLOGY, 1991, 41 (08) : 1219 - 1222
  • [3] RELAPSING-REMITTING MULTIPLE-SCLEROSIS - SEQUENTIAL ENHANCED MR IMAGING VS CLINICAL FINDINGS IN DETERMINING DISEASE-ACTIVITY
    BARKHOF, F
    SCHELTENS, P
    FREQUIN, STFM
    NAUTA, JJP
    TAS, MW
    VALK, J
    HOMMES, OR
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1992, 159 (05) : 1041 - 1047
  • [4] Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI
    Calabresi, PA
    Stone, LA
    Bash, CN
    Frank, JA
    McFarland, HF
    [J]. NEUROLOGY, 1997, 48 (05) : 1446 - 1448
  • [5] Campi A, 1996, NEURORADIOLOGY, V38, P115
  • [6] Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis
    Filippi, M
    Barkhof, F
    Bressi, S
    Yousry, TA
    Miller, DH
    [J]. MULTIPLE SCLEROSIS JOURNAL, 1997, 3 (04) : 226 - 230
  • [7] Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis
    Filippi, M
    Yousry, T
    Rocca, MA
    Fesl, G
    Voltz, R
    Comi, G
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1997, 95 (06): : 331 - 334
  • [8] A high resolution three dimensional T-1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis
    Filippi, M
    Yousry, T
    Horsfield, MA
    Alkadhi, H
    Rovaris, M
    Campi, A
    Voltz, R
    Comi, G
    [J]. ANNALS OF NEUROLOGY, 1996, 40 (06) : 901 - 907
  • [9] COMPARISON OF TRIPLE DOSE VERSUS STANDARD-DOSE GADOLINIUM-DTPA FOR DETECTION OF MRI ENHANCING LESIONS IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE-SCLEROSIS
    FILIPPI, M
    CAMPI, A
    MARTINELLI, V
    COLOMBO, B
    YOUSRY, T
    CANAL, N
    SCOTTI, G
    COMI, G
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1995, 59 (05) : 540 - 544
  • [10] Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS
    Filippi, M
    Yousry, T
    Campi, A
    Kandziora, C
    Colombo, B
    Voltz, R
    Martinelli, V
    Spuler, S
    Bressi, S
    Scotti, G
    Comi, G
    [J]. NEUROLOGY, 1996, 46 (02) : 379 - 384